BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...virus nuclear antigen 1 EGFR (ErbB1; HER1) - Epidermal growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren...
BioCentury | Feb 8, 2020
Targets & Mechanisms

Astellas lays groundwork for oncolytic virus combination therapy

...lead program, RIVAL-01. The preclinical candidate encodes IL-12, an antibody against CTLA-4 and the immunostimulatory FLT3LG...
...NYSE:MRK) for melanoma. Targets CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 FLT3LG - FMS-like tyrosine kinase 3 ligand...
BioCentury | Dec 19, 2019
Company News

Takeda adds oncolytic viruses to pipeline via Turnstone deal

...share global development and commercialization of RIVAL-01, Turnstone’s lead candidate. RIVAL-01 encodes the immunostimulatory factors FLT3LG...
...robust immune response.” Targets: CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; FLT3LG - FMS-like tyrosine kinase 3 ligand...
BioCentury | Sep 18, 2019
Distillery Therapeutics

TAP inhibition for multiple cancers

...in mice with metastatic pancreatic cancer. When given in combination with an anti-PD-1 mAb or FLT3LG...
...of T cell lymphoma or breast cancer. TARGET/MARKER/PATHWAY: Transporter associated with antigen processing (TAP); nucleolin; FMS-like tyrosine kinase 3 ligand (FLT3LG)...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

...Macrophage inflammatory protein-1 β; CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4; FLT3LG - FMS-like tyrosine kinase 3 ligand...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...+ Ad-hCMV-Flt3L Adenoviral vectors expressing Human herpes simplex type 1 (HSV-1) thymidine kinase UL23 and FMS-like tyrosine kinase 3 ligand (FLT3LG)...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...lab is investigating combination strategies to bolster the mechanism. These include activating dendritic cells with FLT3LG...
...Targets AFP - α fetoprotein EGFRvIII - Epidermal growth factor receptor variant III FLT3LG - FMS-like tyrosine kinase 3 ligand...
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-150 (miR-150); FMS-like tyrosine kinase 3 (FLT3; CD135); FMS-like tyrosine kinase 3 ligand (FLT3LG)

...marrow cells from patients with FLT3-driven AML, polymer nanoparticles loaded with miR-150 and conjugated to FLT3LG...
...proliferation compared with miRNA control nanoparticles. In a mouse model of FLT3-driven MLL, the miR-150-loaded, FLT3LG-conjugated...
...toxicity in normal blood cells. Next steps could include testing efficacy and safety of the FLT3LG-conjugated...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: FMS-like tyrosine kinase 3 ligand (FLT3LG); BRAF; programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)

...Cancer INDICATION: Melanoma Mouse studies suggest FLT3LG plus poly I:C could help treat BRAF-mutant melanoma. In...
...could help treat BRAF-mutant melanoma. In a mouse model of BRAF-mutant melanoma, systemic injection of FLT3LG...
...Next steps could include testing FLT3LG plus poly I:C in xenograft models of melanoma. TARGET/MARKER/PATHWAY: FMS-like tyrosine kinase 3 ligand (FLT3LG)...
BioCentury | Mar 7, 2016
Clinical News

CDX-301: Interim Phase II data

...Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-301 Business: Transplant Molecular target: FMS-like tyrosine kinase 3 ligand (FLT3LG) Description: Recombinant human FMS-like tyrosine kinase 3 ligand (FLT3LG)...
Items per page:
1 - 10 of 19